Respiratory Analytics Ltd Secures £415.1k for aflo™ Digital Health Platform

Respiratory Analytics Ltd, a Londonderry-based innovator in digital health, has successfully secured £415.1k in a recent funding round. The capital infusion will support the continued development and expansion of its flagship product, aflo™, a digital platform designed to revolutionise the management of respiratory conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD).

Founded on 14 November 2019, Respiratory Analytics Ltd addresses a critical challenge in respiratory care: the correct use of inhaled medicines. Millions worldwide rely on inhalers, yet improper technique often diminishes their effectiveness, leading to uncontrolled symptoms and increased exacerbation risks. The aflo™ platform tackles this by integrating sensor technology, artificial intelligence, and big data analytics to provide real-time feedback and actionable insights.

The aflo™ ecosystem comprises a data capture device, a user-friendly mobile application, a dedicated clinician portal, and a sophisticated data analytics tool. This comprehensive approach ensures that individuals receive immediate guidance on their inhaler technique, while clinicians gain access to vital patient data and AI-driven insights. Beyond technique correction, aflo™ is designed to aggregate user data with external factors such as air quality and viral data, enabling the platform to identify potential symptom worsening and warn of possible exacerbation risks before they become critical. This proactive approach aims to empower patients and healthcare providers with tools to better control life-threatening symptoms.

Respiratory Analytics Ltd operates from its headquarters in Derry/Londonderry, Northern Ireland, and specialises in respiratory and digital health solutions. The company's LinkedIn profile highlights its commitment to designing and building the next generation of 'smart inhalers', supported by previous funding from organisations such as Innovate UK, Techstart NI, and CoFund. The team currently consists of four employees, according to the latest available accounts, reflecting a lean and focused operation dedicated to its mission.

The recent funding round, estimated at £415.1k, saw its allotment date on 2 April 2026, with the filing date recorded as 7 April 2026. Details regarding the specific investors for this particular round and the company's post-money valuation have not been disclosed. This funding marks a significant step for Respiratory Analytics Ltd as it continues to advance its technology and market reach within the burgeoning digital health sector.

The UK's digital health landscape continues to attract investment, particularly in solutions that leverage AI and data analytics to improve patient outcomes and healthcare efficiency. Respiratory Analytics Ltd's focus on a specific, high-impact area like inhaler technique and exacerbation prediction positions it as a key player in this evolving market. The continued investment in companies like Respiratory Analytics Ltd underscores the recognised potential of technology to transform chronic disease management.